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Patients with systemic autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are prone
to develop atherosclerosis and cardiovascular diseases ﬁve times more often than the general population; this increase in frequency
could be partially explained by an increase in the macrovasculature endothelial damage. In these autoimmune diseases, a
microvascular endothelial injury has also been reported in diﬀerent organs and tissues, especially in sites where ultraﬁltration
processes occur. Diﬀerent components that are characteristic to the immunopathology of RA and SLE could be involved in the
endothelial cell activation, permeability increase, functional alteration, and vascular injury. Circulating immune complexes (IC)
detected in SLE and RA have been proposed to participate in the endothelial injury. In the vascular environment, IC can
generate diﬀerent responses that could be mediated by monocytes, because these cells have patrolling and monitoring functions
on the endothelium. However, with certain stimuli such as TLR ligands, the monocytes are retained in the lumen, releasing
proinﬂammatory mediators that participate in the endothelial damage. This paper aims to review some aspects about the
endothelial activation and dysfunction in the context of SLE and RA, as well as the potential role that monocytes apparently
play in this process.
1. Introduction
Endothelial cells had not been previously considered as a
key component of the immune system; however, there
are growing evidences that show the involvement and
modulation of these cells through innate and adaptive
immune responses [1, 2]. This initial question about their
essential immunological contribution was mainly due to
the endothelial diversity and the variety of functions per-
formed by these cells in the cardiovascular system, for
example, in regulating homeostasis and blood ﬂow [1–4].
Endothelial cell activation and perturbation have been
associated with diﬀerent immunopathological processes,
such as atherosclerosis, diabetes, pulmonary hypertension,
rheumatoid arthritis (RA), systemic lupus erythematosus
(SLE), hemoglobinopathies, and certain infectious diseases
like dengue, among others [1, 3, 5, 6].
In the chronic and systemic inﬂammatory processes
presented in SLE and RA, a gradual deterioration of diﬀer-
ent organs, mainly the endothelial injury leads to an
increased risk of developing complications such as athero-
sclerosis and cardiovascular diseases, which are the most
common causes of premature mortality in patients with
SLE and RA [5]. Diﬀerent genetic, epigenetic, environmental,
hormonal, and immunological factors have been involved in
the establishment of these diseases [7]. In both cases (SLE
andRA), there is immunecomplex (IC) formation anddeposit
in circulation, which could cause direct or indirect endothelial
damage. IC are generated because the autoantibodies recog-
nizes all potential autoantigens present in the blood, in soluble
Hindawi
Mediators of Inﬂammation
Volume 2017, Article ID 9680729, 12 pages
https://doi.org/10.1155/2017/9680729
form or as part of the vesicular structures such as apoptotic
cells (AC) and microparticles (MP) [8–10].
It has been established that monocytes and macrophages
play a central role in the immunopathology of SLE and RA,
principally by removing autoantigens and IC, migrating into
the site of inﬂammation, and by the production of proinﬂam-
matory factors such as interleukin- (IL-) 1β and tumor
necrosis factor- (TNF-) α and chemokines like IL-8, reactive
oxygen species (ROS), and nitric oxide (NO) [11, 12]. Mono-
cytes have been described as the main patrolling cells of the
endothelium maintaining the integrity of this tissue in basal
conditions; however, the IC presence and deposit in the vas-
culature might modulate the endothelial microenvironment,
changing the interaction and responses of monocytes to this
tissue and compromising the endothelium integrity. There-
fore, monocytes should participate in endothelial dysfunc-
tion presented in RA and SLE patients. In this paper, we
reviewed the information regarding the activation and endo-
thelial alterations in the context of SLE and RA, and the
current knowledge of how monocytes participate in both
the activation of endothelial cells, as well as their damage.
In addition, we propose a possible mechanism by which
the monocyte subpopulations interact with the endothelial
cells favoring their alterations in the macro- and microvas-
cular context of SLE and RA; however, this model is limited
due to the scarce information available regarding this topic
at this moment.
2. Overview of Endothelial Cells
Endothelial cells coat the inner wall of the blood vessels
forming a single layer of cells called endothelium. These cells
can be part of the macrovasculature (large vessels with an
internal diameter ≥ 100 μm), which is made up of three
layers: intima, media, and adventitia [13]. The endothelial
cells are also part of the microvasculature (small vessels with
an internal < 100 μm) that includes arterioles, venules, and
capillaries, integrated with endothelial cells and pericytes
(perivascular contractile cells “Rouget cells”) to maintain the
integrity of this vascular wall [13].
From the earliest stages of embryonic organ develop-
ment, it is apparent that vessels are not merely conduits for
blood, nutrients, gas exchange, and waste disposal; instead,
they are essential components of diﬀerent tissues for their
functions and specialization. Therefore, endothelial cells spe-
cialize in each tissue, displaying unique organ-associated
antigens. For this reason, they are very heterogeneous and
have specialized roles in diﬀerent locations as well as show
variations in response to stimuli, injury, and repair which
determine the disease patterns [4]. Nowadays, growing
evidence in this ﬁeld shows that the microvascular endothe-
lial cells (MIEC) diﬀer in phenotype, gene expression, and
physiology than macrovascular endothelial cells [14].
Human umbilical vein endothelial cells (HUVEC) proliferate
well in serum-containing medium and seem to be less
demanding in endothelial growth factors than MIEC, reﬂect-
ing diﬀerences in the machinery regulating cell cycle between
these cells [15]. The amount of vasoactive substances
(endothelin-1, thromboxane, angiotensin II, andprostacyclin)
released into the culturemediumby these cells is also diﬀerent,
for example, MIEC secrete 2-fold higher quantity of
angiotensin-II thanHUVEC [16]. Therefore, endothelial cells
are morphologically and functionally heterogeneous with the
greatest diﬀerences between those that are from the macro-
and microcirculation.
At the luminal side (inner side), the endothelium is
exposed to blood components and serves as a containment
barrier for blood components, while on its external face,
endothelial cells are directly communicated with smooth
muscle cells or pericytes by myoendothelial gap junctions,
allowing transfer of ions and small molecules such as calcium
to supply metabolic needs [2, 17]. Three types of intercellular
junctions between the adjacent endothelial cells have been
described: they are tight, gap, and adherent junctions. Their
distribution changes along the vasculature because the
expression and organization of these connections depends
on vessel size and permeability requirements of the perfused
organs [17]. Additionally, the endothelium is considered the
main regulator of vascular homeostasis that controls vascular
tone, blood ﬂow, angiogenesis, and hemostasis and in some
cases regulating thrombosis, thrombolysis, and platelet
adhesion [1, 2]. All these responses occur in the presence of
diﬀerent stimuli such as hormones, cytokines, and physical
and chemical changes (e.g., changes in pressure, pH).
Figure 1 shows the main molecules secreted by the endothe-
lium that are involved in vascular homeostasis.
Changes that aﬀect the endothelium function include the
increase of oxidative stress, reduction of NO bioavailability,
ﬂuctuations in blood pressure, alterations in prostanoid
production, increase of endothelin production, decline of
the endothelial cells hyperpolarization, among others [6].
The term “endothelial dysfunction” was established in
the early eighties after Furchgott and Zawadzki discov-
ered that the eﬀect of acetylcholine in the relaxation of
vascular smooth muscle requires the presence of endothelial
cells [18]. Endothelial dysfunction was initially described as
an early event that trigger defects in the vascular wall and was
strongly associated with the development of atherosclerosis
in humans [19]. However, this term is not only related to
hypertensive changes but also refers to damage processes of
endothelial cells with physiological and pathological aging
processes such as kidney damage, intravascular coagulation,
diabetes, obesity, atherosclerosis, hypercholesterolemia,
sepsis, trauma, infectious, and inﬂammatory diseases such as
RA, SLE, and vasculitis among others [1, 6, 20].
Although the immune system has been considered a
potential inducer of endothelial dysfunction, for example,
through the presence of speciﬁc autoantibodies against
the endothelium (autoimmune responses), the precise eti-
ology of endothelial damage initiation in an inﬂammatory
context is still an enigma. Innate immune responses have
not been carefully studied to be directly responsible for
the original dysfunction; nevertheless, it is accepted as
ampliﬁers and setters of the endothelial injury [20]. There-
fore, it is important to recognize and understand the
phases of initiationandprogressionof endothelialdysfunction
in pathologies with inﬂammatory components, which allows
elucidation of potential targets that could be modulated
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pharmacologically for restoring normal structure and func-
tionality of this tissue.
3. The Endothelium and Immune Responses
Endothelial cells are involved in anti- and proinﬂammatory
immune responses because they produce diﬀerent soluble
factors and express adhesion molecules that recognize and
allow for leukocyte adherence, rolling, and extravasation [2,
3]. Endothelial cells secrete a variety of cytokines such as
IL-1β, IL-6, IL-8, and granulocyte-macrophage colony-
stimulating factor (GM-CSF) in response to hypoxemia,
several bacterial products, and cytokines such as TNF-α,
among other inducers [2, 3]. These mediators have an eﬀect
on cells from the innate and adaptive immune system,
mediating their recruitment and cell turnover.
One of the main functions attributed to the endothe-
lium in the context of the immune responses is leukocyte
transmigration, from the vascular lumen into the tissues;
this is a determinant event for the initiation and resolution
of diﬀerent inﬂammatory processes. Leukocyte migration
involves the contribution of a variety of adhesion molecules,
which mediate their direct interaction with endothelial cells,
such as lectins CD62P and CD62E and the glycoproteins
ICAM-1, ICAM-2, VCAM-1, and CD99 [2, 21–23]. Some
general aspects of cell adhesion molecules and chemokines
involved in leukocyte-endothelial interaction are summarized
in Table 1.
Previous studies have shown that the deposit of speciﬁc
autoantibodies on the endothelium in murine models of
autoimmunity and in vitro approaches with HUVEC may
contribute to endothelial damage. Antibodies against endo-
thelial cells (antiendothelial cell antibodies (AECA)) can be
potentially pathogenic as they are involved in the activation
of endothelial cells; promoting the expression of adhesion
molecules like E-selectin, VCAM-1, and ICAM-1; increasing
the production of inﬂammatory cytokines and chemokines
(IL-1β, TNF-α, CX3CL1—fractalkine, etc.); facilitating leu-
kocyte recruitment; and promoting apoptosis and necrosis
of endothelial cells [8, 20]. Furthermore, AECA may contrib-
ute to the inﬂammatory process in situ activating comple-
ment by the classical pathway and increasing cell
cytotoxicity [20].
Caterina et al. in 1995 stimulated human saphenuos vein
endothelial cells (HSVEC) with diﬀerent cytokines (IL-1α,
IL-1β, IL-4, and TNF-α) and NO, in order to determine
whether this radical modulates the endothelial activation
induced by these soluble factors. NO inhibited the expression
of VCAM-1 and E-selectin and the secretion of IL-6 and IL-8;
in addition, it decreased human monocyte adhesion to the
endothelial monolayer. This shows that.NO not only is exclu-
sively involved in the maintenance of vascular tone but also
restricts endothelial activation possibly contributing to the
anti-inﬂammatory and antiatherogenic state that should
characterize vascular walls of healthy individuals with low
risk factors of cardiovascular diseases [24].
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Figure 1: Principal molecules expressed and produced by endothelial cells that are involved in the control of vascular tone, blood ﬂow,
hemostasis, and proinﬂammatory responses.
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In addition to diapedesis, it has been proposed that an
immune response in situ that favors preservation or mediates
endothelial injury might exist in endothelial tissue. MIEC
from C57/BL56 mice mediated the transmigration of Ly6CLo
monocytes to aﬀected tissues in response to the toll-like
receptor- (TLR-) 4 ligands as lipopolysaccharide (LPS), while
TLR-7 ligands (resiquimod) induced the intravascular reten-
tion of those monocytes promoting endothelial damage [25].
Therefore, it was proposed that immune endothelial alter-
ations depend on the way these cells are activated. Endothe-
lial compromise can also be mediated by antibodies that form
IC in circulation, which could bind to complement, and the
Fc receptors on monocytes and neutrophils, producing pro-
inﬂammatory mediators, reactive oxygen species, and delete-
rious enzymes [20].
Autoantibodies against neutrophils and monocytes can
induce a commitment of these cells, but could also promote
endothelial alterations with vascular inﬂammation. van der
Woude et al. in 1985 detected autoantibodies of the IgG iso-
type against the extracellular components of granulocytes
and monocytes in 25 of 27 patients with active granulomato-
sis with polyangiitis (Wegener’s granulomatosis) which had
vasculitis, and in 4 of 32 samples from patients with inactive
disease [26]. In the last years, it has been described that
neutrophils play a pivotal role in the pathophysiology of
antineutrophil cytoplasmic antibody- (ANCA-) positive vas-
culitis, such as in granulomatosis with polyangiitis. These
cells can be the source of autoantigens, are activated by the
ANCA, and are eﬀector cells of the endothelium damage
[27, 28]. Therefore, it is not clear if monocytes could have
the same role in this and other autoimmune diseases regard-
ing endothelial dysfunction. The evidences presented until
now suggest that intravascular phagocytes and their products
play an important role in mediating endothelial damage.
4. Monocytes and Endothelial Damage
It has been demonstrated that monocytes play a dual role in
endothelial patrolling, depending upon their activation stage.
They have monitoring functions and removal of AC, MP,
and other debris in a steady state to preserve the endothelium
integral structure [29, 30]. Contrarily, under proinﬂamma-
tory stages, these phagocytes contribute to the secretion of
mediators of endothelial damage, such as reactive oxygen
species, IL-1β, and TNF-α [31].
According to CD14 and CD16 expression, the monocytes
from human peripheral blood are divided into three subpop-
ulations, CD14++CD16− classical, CD14+CD16++ nonclassi-
cal, and CD14++CD16+ intermediate [32]. The gene proﬁle
and chemokine receptor expression showed that Ly6C+
CCR2+ mouse monocytes correspond with the classical and
intermediate human monocytes, while Ly6C−/LoCX3CR1+
mouse monocytes correspond to nonclassical human mono-
cytes [33].
The recruitment of monocyte subpopulations to diﬀer-
ent tissues is regulated by endothelial microenvironment
involving local production of cytokines and chemokines
(Table 1) [34]. Classical and nonclassical monocytes have
Table 1: Molecules involved in the interaction between leukocytes and endothelium [35, 36].
Family Molecule Cellular distribution Ligand cell type
Selectin
P-selectin (CD62P)
Endothelium activated by histamine
or thrombin
Sialyl Lewis X in PSGL-1 (P-selectin glycoprotein
ligand-1)
present in neutrophils, monocytes, and T cells
(eﬀector and memory) [56].
E-selectin (CD62E)
Endothelium activated by cytokines
(TNF-α, IL-1β)
Sialyl Lewis X in CLA-1 (cutaneous
lymphocyte-associated antigen-1) present
in neutrophils, monocytes, and T cells (eﬀector
and memory) [23].
L-selectin (CD62L)
Neutrophils, monocytes, and T and
B cells in constitutive form
Sialyl Lewis X/PNAd in GlyCAM-1 (glycosylation-
dependent cell adhesion molecule-1), CD34, and
MadCAM-1 (mucosal vascular address in cell
adhesion molecule 1) present in endothelium [57].
Immunoglobulin
ICAM-1 (CD54)
Endothelium activated by cytokines
(TNF-α, IL-1β), macrophages, and
lymphocytes
LFA-1 (CD11a/CD18) in neutrophils, monocytes,
T cells (naive, eﬀector and memory), and B cells
(naive).
Mac-1 (CD11b/CD18) in neutrophils, monocytes,
and dendritic cells [2].
ICAM-2 (CD102) Endothelium in a constitutive form Similar to ICAM-1 [2].
VCAM-1
Endothelium activated by cytokines
(TNF-α, IL-1β)
VLA-4 (CD49a/CD29) in neutrophils, monocytes
and T cells (naive, eﬀector and memory).
α4β7 (CD49d/CD29) in monocytes, T cells (naive,
eﬀector and memory), and B cells [58].
Chemokine CX3CR1
T cells, monocytes, and NK cells
in a constitutive form
CX3CL1 in endothelial cells [36].
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diﬀerent migration patterns [34–36]. CD14++CD16− mono-
cytes preferentially express CCR2, while CD14+CD16++
exhibit high expression of CCR5; CCR1 expression is equiv-
alent in both subpopulations [35]. Weber et al. in 2000 dem-
onstrated that sorted CD16− human monocytes migrated
through HUVEC endothelial cells in response to MCP-1
(monocyte chemotactic protein-1), and this event was due
to the higher expression of CCR2, while the migration of
CD16+ monocytes in response to MIP-1α (macrophage
inﬂammatory protein-1α) was due to their higher expression
of CCR5 [35] (Figure 2(a)). Ancuta et al. in 2003 found that
CD16+ monocytes had high levels of CX3CR1 and CXCR4
and low levels of CCR2 and CD62L and exhibited eﬃcient
migration through HUVEC cells transfected with a plasmid
containing the fractalkine gene (CX3CL1) [36]. These results
showed that the CX3CR1/CX3CL1 pathway appears to
contribute to the interaction of some monocytes with
endothelial cells [36].
Fractalkine (CX3CL1) is the only transmembrane che-
mokine that functions as a cell adhesion molecule by binding
to CX3CR1; however, it may also be cleaved into a soluble
fragment which is recognized by the same receptor [23].
Fractalkine expression in the endothelial cells is constitutive
and can be induced by inﬂammatory cytokines, such as
TNF-α, IL-1β, and IFN-γ [3]. Fractalkine participates in
weak and strong interactions between endothelial cells and
leukocytes; with P- and E-selectins, it mediates initial interac-
tion or rolling, while with integrins, it mediates ﬁrm adher-
ence and facilitate leukocyte extravasation [23]. It was
observed that the CXC3R1 protein and mRNA expression
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CD14++CD16‑
CD14++CD16+
CD14+CD16++
Selectins
Integrins
Fractalkine
Fc훾R
TNF-훼
Adhesion
Endothelial
damage
Steady state
Activation
IL-1훽
Patrolling
(a) Macrovasculature.
CCR2 
CX3CR1
CCL2
AC
IC
Cellular damage
Adhesion
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TNF-훼
Rolling 
Endothelial
damage
Steady state
PatrollingActivation
IL-1훽
(b) Microvasculature.
Figure 2: Interaction of monocytes with endothelial cells. Monocyte subpopulations at steady state are involved in maintenance of
endothelial integrity by removing MP, AC, and other cellular debris; however, after an inﬂammatory environment, monocytes may
diﬀerentially contribute to endothelial damage depending on the subpopulation, kind of stimulus, and endothelium type where immune
response is generated. (a) CD14++CD16− classical monocytes are preferably adhered to macrovasculature endothelium, patrolling and
monitoring large vessels at steady state. Under inﬂammatory stimuli such as TNF-α, which activates endothelial cells, CD14++CD16−
monocytes migrate to the inﬂammation site in response to CCL2 (MCP-1) and amplify the inﬂammatory reaction. CD14++CD16+
intermediate monocytes are weakly adhered to both kind of endothelium and are mainly producers of IL-1β and TNF-α after stimulation
with TLR4 agonist. (b) CD14+CD16++ nonclassical monocytes are preferably adhered to microvasculature, patrolling this type of
endothelium by interactions with CX3CR1. Depending on the stimulus, for example, in response to bacterial infection or tissue damage,
CD14+CD16++ monocytes can migrate to the inﬂammation site (by CX3CL1). Please notice that the graph only shows some components
of the vascular wall and some membrane proteins that express monocyte subpopulations and endothelial cells.
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is reduced in total monocytes from sepsis patients, whereas
CX3CL1 concentration was elevated in serum, suggesting
that monocytes from sepsis patients are retained in circula-
tion because of CX3CL1 levels and CXC3R1 expression,
preventing their recruitment to the focus of infection [37].
In the last years, it has been described in the murine
model that Ly6C−/LoCX3CR1+ monocytes are enriched in
the marginal zone of blood vessels. Auﬀray et al. in 2007
studied the behavior and function of monocytes in vivo in
the steady state and under inﬂammatory conditions; for this
propose, they monitored the vasculature of Rag2
−/− Cx3cr1
gfp+
mice by intravital microscopy, after the adoptive transfer of
human monocyte subpopulations labeled with ﬂuorescent
probes. At steady state, the human and murine monocytes
were in close contact with the endothelium (at the dermis
blood vessels and in the branches of the mesenteric artery)
and in the presence of the constant blood ﬂow; these cells
had a patrolling movement on the blood vessels depending
on the LFA-1 and CX3CR1. Extravasation of these cells was
not observed during the period evaluated. After proinﬂam-
matory stimuli, such as tissue mechanical damage or perito-
neal infection with the intracellular bacterium Listeria
monocytogenes, these monocytes were quickly recruited
(one hour) to the aﬀected site, resulting in high levels of
TNF-α and IL-1β. Therefore, researchers proposed that
Ly6C−/Lo monocytes may be the ﬁrst line of cells to respond
to the inﬂammatory events that produces high amounts of
proinﬂammatory cytokines, which could increase the extrav-
asation of further components of the immune system [29].
In another study of the same group, it was found that
steady Ly6C−/Lo monocytes patrol the endothelium to
remove MP and AC through interactions depending on
LFA-1 and ICAM-1 adhesion molecules [25]. Intravascular
retention (without diapedesis) of these monocytes was
observed in response to pathogen-associated molecular pat-
terns (PAMP) such as a TLR-7 ligand but not with a TLR-4
ligand, in a way that depends on fractalkine expression. In
addition, neutrophil recruitment was also promoted to the
aﬀected site, with a consequent induction of endothelial
damage inside the vascular lumen [25].
Concordantly, there is evidence that suggests that human
CD14+CD16++ (the counterpart of the murine Ly6C−/Lo
monocytes) also have close contact with the endothelium
[33]. In humans, it was shown that over 75% of
CD14+CD16++CX3CR1+ monocytes are found in the mar-
ginal zone of the blood vessels. These cells apparently reside
in this location and interact with endothelial cells by the
expression of a variety of adhesion molecules such as
CD11b and VLA-4. These monocytes are mobilized from
the marginal zone of the vessels by nonspeciﬁc stimuli such
as anaerobic exercise, increasing their circulating numbers
in minutes [38].
Cros et al. in 2010 characterized the functions of human
CD14+CD16++ in samples isolated from healthy people and
MYD88 or IRAK-4-deﬁcient patients (autosomal recessive
defect); they compared these results with murine Ly6C−/Lo
monocytes. At steady state, the human monocytes showed
an anti-inﬂammatory proﬁle; but after infection with
diﬀerent viruses (herpes simplex type I and measles) and
treatment with IC containing nucleic acids, these cells
produced TNF-α, IL-1β, and CCL3, through the stimulation
of TLR7, TLR8, MyD88, andMEK activation pathways. Until
now, results have suggested that the CD14+CD16++ mono-
cytes patrol the endothelium, detecting viral infections and
IC and producing proinﬂammatory cytokines in response
to these stimuli. Furthermore, in this research, it was pro-
posed that the activation of monocytes by IC and nucleic
acids could contribute to autoimmune disease pathogenesis
such as SLE, because of the accumulation of IC in the micro-
vasculature of diﬀerent tissues, particularly in the renal
glomerulus [33] (Figure 2(b)).
Collison et al. in 2015 evaluated the locomotion of
monocyte subpopulations during adhesion to endothelial
cells using human cells. After the separation of three mono-
cyte subpopulations from healthy persons, the cells were
cocultured with macrovasculature (HUVEC) and microvas-
culature (human dermal blood endothelial cells (HDBEC))
endothelial cells under a shear ﬂow system. Each subpopula-
tion showed diﬀerent locomotion patterns depending on the
type of endothelial cell. CD14++CD16− monocytes were
preferably adhered to HUVEC, arrested in the monolayer,
and showed patrolling behavior, while CD14++CD16+ and
CD14+CD16++ monocytes did preferably bond to HDBEC.
Only the CD14+CD16++ monocytes crawled long distances
exerting a patrolling movement. Each form of locomotion
had a diﬀerent requirement for adhesion molecules; in par-
ticular, the long-range crawling behavior in CD14+CD16++
monocytes was abrogated by blockade of ICAM1, VCAM1,
or CX3CL1, whereas this behavior in CD14++CD16− mono-
cytes was stopped by blockade of ICAM1. Upon activation
of the endothelial cells by TNF-α, the expression of CX3CL1
increased in the macro- and microvasculature; hence, the
migration of CD14++CD16− and CD14+CD16++ monocytes
was observed. This study demonstrated the diﬀerential
behavior and locomotion heterogeneity that monocyte
subpopulations present in endothelial cells before and after
activation stimuli [30] (Figure 2).
These evidences show that both murine and human
monocytes interact directly with the endothelium, they have
surveillance and patrolling functions, and these functions
apparently depend on the subpopulation involved. However,
under certain stimuli and proinﬂammatory responses, these
phagocytes could participate in endothelial damage. Little is
known of how these monocytes interact with micro- and
macrovasculature endothelial cells in the context of RA and
SLE and if they could be contributing to endothelial dysfunc-
tion in these pathologies.
5. Endothelial Alterations in SLE and RA:
Potential Contribution of Monocytes
Endothelial alterations in both micro- and macrovasculature
have been demonstrated in patients with RA and SLE evalu-
ated by FMD (ﬂow motion dilation) of the brachial artery,
assessing arterial stiﬀness and thickening of carotid intima-
media (the intima-media thickness (IMT)), among other
tests [39]. These studies have shown that these vascular
changes are positively correlated with the inﬂammatory
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status of patients using the measurement of acute phase pro-
teins (C-reactive protein and IL-6), with chronic use of corti-
costeroids and clinical activity of the diseases [40]. In fact, RA
and SLE patients have an endothelial dysfunction associated
with an increased risk of developing atherosclerosis and car-
diovascular diseases, which reduce their life expectancy by
10–15 years [5]. In general, the pathways and mechanisms
involved in the initial endothelial damage in SLE and RA
patients are still not known; however, it is postulated that it
can be partly due to the immune system activation, chronic
inﬂammation, and oxidative stress presented in these indi-
viduals. The immunological mechanisms which can lead to
endothelial dysfunction in SLE and RA included mainly
type II (cytotoxic reactions) and type III (immune
complex injury) hypersensitivity reactions; however, it is
possible that other mechanisms can also activate the
immune system and promote inﬂammation in these auto-
immune diseases [41, 42].
5.1. Endothelial Alterations in SLE. SLE is a chronic systemic
autoimmune disease, characterized by loss of immunological
tolerance of B cells, with the subsequent autoantibody pro-
duction against double-stranded DNA, nuclear proteins such
as Smith (Sm) and phospholipids, among others [8, 9]. These
antibodies may directly bind to endothelial cells or are part of
the circulating IC that can be deposited in the vessels, pro-
moting inﬂammatory responses of innate immune cells and
increasing endothelial permeability and leukocyte inﬁltration
to the aﬀected tissues [9]. In addition, the continuous expo-
sure of patrolling monocytes of these patients to circulating
autoantibodies and IC may also lead to chronic endothelial
cell activation mediated by the interaction with monocytes,
causing injuries of blood vessels and vasculitis [43].
Pentraxin 3 (PTX3), which is produced by endothelial
cells in response to various inﬂammatory events, has been
proposed as an indicator of inﬂammatory vascular injury
and as a biomarker of vasculitis in SLE and other diseases
such as sepsis, septic shock, and preeclampsia. This protein
binds with high aﬃnity to C1q and it is involved in repairing
the blood vessels, mediating angiogenesis, atherosclerosis,
and restenosis, among others [43]. The PTX3 levels and other
indicators of endothelial dysfunction (like the soluble form of
E-selectin (sE-selectin), VCAM-1 (sVCAM-1), MCP-1
(monocyte chemotactic protein-1), and von Willebrand factor
(vWF)) were estimated in plasma and serum of 56 women
with SLE. These patients had high concentrations of PTX3,
vWF, MCP-1, sE-selectin, and sVCAM-1 compared to
healthy controls. The expression levels of PTX3 were also
associated with the activity index, the prednisolone dose
received, the severity of anemia present in those patients,
and vWF and sVCAM-1 levels. Therefore, it was concluded
that the concentration of PTX3 may be an indicator of endo-
thelial activation or dysfunction in SLE patients [43].
Daha et al. in 1988 showed that the puriﬁed human C1q
labeled with iodine 125 (I-125) could interact with HUVEC
by collagen binding region and maybe through PTX3. When
HUVEC was incubated with IC formed by bovine thyroglob-
ulin (BTg) and rabbit antibodies against BTg, the binding of
those IC to endothelium increased with the presence of C1q
[44]. This suggests that antibodies forming IC with speciﬁc-
ities other than endothelium molecules could also deposit
on endothelial cells through a classical complement compo-
nent, boosting innate immune response.
Other studies reported that alterations in the coagulation
and thrombus formation in SLE patients is associated with
the presence of antiphospholipid antibodies: anticardiolipin,
anti-β2-glycoprotein and LA [9]. These antibodies bind to
the negative surface of the phospholipids in endothelial cells,
preventing the union of the inhibitors of coagulation, like
the tissue factor pathway inhibitor (TFPI) or the protein
C-protein S complex to the cell surface, hence causing the
activation and aggregation of platelets and thrombus forma-
tion. These antibodies could also induce endothelial damage
in a similar way. In fact, it was demonstrated that some
speciﬁc autoantibodies against phospholipids can activate
endothelial cells, inducing membrane expression of ICAM-
1, VCAM-1, and E-selectin and also increases the expression
of tissue factor in endothelial cells and monocytes from SLE
patients [45].
Martini et al. in 1996 investigated the presence of
phospholipids antibodies, anticardiolipin (aCL), and lupus
anticoagulant (LA) in serum of 22 SLE patients by ELISA
and KCT (kaolin clotting time) coagulation test. The results
showed that 54.5% of SLE patients were positive for LA,
64% for aCL, and 59% for both factors (aCL and AL). Subse-
quently, the tissue factor productions by monocyte (mono-
cyte procoagulant activity (MPA)) from the controls
exposed to plasma from SLE patients were evaluated. The
MPA was signiﬁcantly increased with the serum from
patients who were aCL-positive and/or LA+, compared with
SLE patients without these autoantibodies. These results
show that the presence of aCL and/or LA in SLE patients is
associated with the increase in monocyte activation, thereby
promoting the occurrence of thrombotic events in these
patients [46]. The results also suggest that this class of auto-
antibodies could mediate endothelial dysfunction indirectly
by inducing activation of monocytes (Figure 3).
AECA have been found in the sera from SLE patients;
however, the mechanism by which these antibodies are
involved in the development of endothelial dysfunction is
not yet completely understood. Moscato et al. in 2002 sepa-
rated anti-DNA and other autoantibodies from the serum
of SLE patients by aﬃnity chromatography and assessed their
binding to HUVEC cells using immunoprecipitation and
ﬂow cytometry. Both classes of antibodies recognized diﬀer-
ent membrane components of the endothelial cells; however,
this binding did not induce cytotoxicity by complement or
apoptosis, suggesting that anti-DNA and other autoanti-
bodies can recognize the surface of HUVEC but do not
appear to be directly responsible for endothelial dysfunction
[8]. However, if these antibodies are bound to the endothe-
lium and are recognized by the patrolling monocytes, it
would promote the damage of these cells.
Renal involvement includes the most serious aﬀections of
SLE. Monocytes, macrophages, and T lymphocytes play a
critical role in the initiation and progression of lupus nephri-
tis; these cells can cause an increase in endothelial
permeability by proinﬂammatory cytokine production and
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cytotoxic reactions (by autoantibodies or complement sys-
tem) that allow the immune cell inﬁltration of the glomeruli
and interstitium and ﬁnally kidney damage [47]. Yoshimoto
et al. in 2007 studied the association among the fractalkine
expression in the glomerular capillaries, the inﬁltration of
CD16+ monocytes in response to this chemokine, and the
severity of glomerular lesions in patients with renal involve-
ment. They collected renal biopsies from patients with
diﬀerent kinds of nephritis (I–V), and performed histopath-
ological and immunohistochemical studies, as well as RNA
extraction and RT-PCR (reverse transcription polymerase
chain). Patients with proliferative lupus nephritis (class III
and IV) had signiﬁcantly higher expression of fractalkine
and higher amount of CD16+CX3CR1+ monocyte inﬁltra-
tion than the control biopsies. Furthermore, the glomerular
fractalkine expression correlated signiﬁcantly with
histopathologic activity index and the amount of CD16+
monocytes; this last variable also correlated with serum
levels of urea, complement, and anti-DNA. These ﬁndings
suggest that monocytes appear to respond eﬀectively to
changes observed in the endothelium, hence contributing
to disease pathology; however, the initial stimuli that triggers
the endothelial activation, dysfunction, and nephritis in SLE
is still unknown [47].
Mikolajczyk et al. in 2015 investigated the relationship
between atherosclerosis, endothelial dysfunction, and mono-
cyte phenotype in SLE patients [48]. They characterized the
monocyte subpopulations in peripheral blood samples from
42 SLE patients and determined the IMT of the carotid arter-
ies (with ultrasonographic) as an indication of atherogenesis,
and FMD and NMD (nitroglycerin-induced dilation) as indi-
cators of endothelial dysfunction. SLE patients showed
increased thickness of carotid arteries and endothelial dys-
function when compared to controls by IMT and FMD,
respectively; IMT data correlated positively with an increase
in the frequency of CD14+CD16++ subpopulation. In addi-
tion, an increase in CD14++CD16+ monocytes was observed
in SLE patients compared to healthy controls [48]. Thus, it
could be proposed that CD14+CD16++ monocytes are related
to atherosclerosis in SLE patients; however, it is not clear
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Figure 3: Endothelial alterations in SLE and RA. The binding of autoantibodies to the endothelium and deposition of IC on the
microvasculature lead to classical complement and monocyte activation and increased endothelial permeability by alterations of
interendothelial junctions. There is also increased cell cytotoxicity by immune cells, which further aﬀects the integrity of the tissue. This
endothelial activation and damage produce an acute inﬂammatory response, which recruit further innate immune cells as neutrophils and
other monocytes, induce platelet aggregation with the consequent procoagulant activity and microthrombus formation. These
inﬂammatory events can aﬀect diﬀerent organs and tissues such as kidney in LES (red) and joint in AR (blue), which contribute to the
pathogenesis of these diseases. Finally, the persistence of these inﬂammatory events could conduce to a macrovascular endothelial
alterations and chronic inﬂammatory process that leads to the development of complications in larger vessels, such as atherosclerosis and
cardiovascular disease. Please notice that the graph only shows some components of the vascular wall and some membrane proteins that
express monocyte subpopulations and endothelial cells; in addition, it is important to clarify that the graph does not show diﬀerences
between macro- and microvasculature.
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whether these cells could be involved in the endothelial
dysfunction that occurs in this disease.
The evidences have shown that endothelial alterations in
SLE can be associated with autoantibodies against phospho-
lipids that activate endothelial cells and cause damage (type
II hypersensitivity reaction), also circulating IC that induce
innate immune responses, including monocytes, and trigger
type III hypersensitivity reactions. Although it is clear that
monocyte subpopulations in SLE have diﬀerent alterations
in their proportion in circulation, little is known about the
changes in their phenotype, the interaction they have with
endothelial cells, and their role in the development of endo-
thelial dysfunction and atherosclerosis in this disease. There-
fore, it is proposed that the activation of patrolling
monocytes, for example, by IC recognition, could induce
classical activation of these cells with consequent induction
of a proinﬂammatory environment. This would begin endo-
thelial dysfunction in macrovasculature and atherosclerosis,
as well as contribute to the damage of endothelium from
microvasculature in diﬀerent target organs such as the skin
and kidney (Figure 3).
5.2. Endothelial Alterations in RA. RA is a chronic systemic
inﬂammatory disease characterized by persistent involve-
ment of diﬀerent joints. RA patients have a high risk of
developing atherosclerosis and consequently cardiovascular
disease; 30–50% of RA patients die for these causes. This is
partly because these patients have diﬀerent endothelial alter-
ations, such as persistent activation, prothrombotic proper-
ties, and a reduction on vasodilator response [49–51].
Bergholm et al. in 2002 were the ﬁrst to identify endothelial
dysfunction in RA patients. They found that the vasodilator
response of the intrabrachial artery to acetylcholine and
sodium nitroprusside infusions was lower in 10 newly
diagnosed RA patients (maximum 18 months after the
diagnostic) than the response of healthy controls. This sug-
gests the presence of early endothelial dysfunction in these
patients [50].
The endothelial dysfunction has been described as an
integral part of the pathogenesis of RA, because the inﬂam-
matory condition that occurs in this disease primarily aﬀects
small and medium vessels (microvasculature), causing even
rheumatoid vasculitis (RV). These patients have a vast array
of clinical manifestations with a predilection for the skin
(peripheral gangrene, deep cutaneous ulcers) and the periph-
eral nervous system (mononeuritis multiplex). Systemic
vasculitis in RA has been associated with high levels of
rheumatoid factor (RF) and increased amounts of anti-C1q,
AECA, and anti-glucose-6-phosphate isomerase, among
others [52], suggesting that similar to SLE, the autoantibodies
apparently perform an important role in the endothelial
alterations. Siegert et al. in 1990 investigated the presence
of IgG and IgA antibodies that bound to C1q (as a measure
of circulating IC) in serum samples from 80 RA patients
without RV, 31 patients with RV, and 80 healthy controls.
The IgG and IgA antibodies bound to C1q were detected in
only 5% of RA patients without RV, while 29% and 61% of
patients with RV had IgG and IgA antibodies bound to
C1q, respectively. Therefore, it was shown that IgG and IgA
antibodies contribute to the formation of circulating IC in
RA patients and suggest that they are associated with the
development of RV [53].
Increased levels of endothelial progenitor cells (EPC)
were observed in the synovial ﬂuid of RA patients compared
with circulation levels of the same patients. This recruitment
of the EPC to synovia was associated with blood vessel
formation in this region (angiogenesis) and with a reduction
in the number of these cells in circulation. This could
increase cardiovascular risk, because it possibly disturbs the
ability of these patients to repair the endothelium and to do
revascularization of the ischemic and aﬀected areas [40].
It is estimated that 60% of RA patients suﬀer chronic
synovitis that eventually destroys the joint. It has been
suggested that circulating monocytes play an important role
in chronic synovitis, because they primarily inﬁltrate the
joint and produce inﬂammatory cytokines (IL-1β, IL-6, and
TNF-α) [31]. Grober et al. in 1992 evaluated mononuclear
cell interaction with microvasculature endothelial cells,
which were obtained from knee synovial tissue or the hip of
patients with chronic RA after arthroplasty. The endothelial
cells were incubated with monocytes or lymphocytes
obtained from peripheral blood of the patients, and the cell-
cell interaction were analyzed by confocal microscopy (bind-
ing assay Stamper-Woodruﬀ). The observation revealed that
the monocytes were bound more frequently to the endothe-
lium than the lymphocytes; in addition, blocking P-selectin
with a neutralizing antibody reduced more than 90% of the
monocyte adhesion to the synovial microvasculature, while
no change was observed by blocking E-selectin, L-selectin,
LFA-1, and β2 integrin. This study suggests that the inter-
action of monocytes with endothelial cells of RA patients
byP-selectin couldmediate the inﬁltrationof thesephagocytes
to synovial tissue [31].However, it is important todemonstrate
if those interactions could promote the endothelial alterations
of these patients.
Ruth et al. in 2001evaluated the expressionofCX3CL1and
CX3CR1 receptor by immunohistochemistry in experimental
arthritis model associated with Mycobacterium butyricum in
Lewis rats. The macrophages, ﬁbroblasts, and dendritic cells
at the synovial tissue expressed both fractalkine and its
receptor, whereas the endothelial cells only expressed
CX3CL1. Furthermore, an increase in CX3CR1 and CX3CL1
mRNA was also found in the ankle when rats showed severe
inﬂammation [54]. The same authors also evaluated the
expression of CX3CL1 and its receptor in peripheral blood
samples and synovial ﬂuid of patients with RA, osteoarthritis,
juvenile rheumatoid arthritis, psoriatic arthritis, polyarthritis,
spondyloarthropathy, inﬂammatory myopathy, and gout.
They found similar results, showing that macrophages, ﬁbro-
blasts, endothelial cells, anddendritic cells expressedCX3CL1;
in addition, the macrophages and dendritic cells were also
positive for CX3CR1. By ELISA, they observed high levels of
soluble fractalkine fragment at the synovial ﬂuid of RA
patients, compared to patients with osteoarthritis and other
forms of arthritis. The in vitro blockade of fractalkine
presented in synovial ﬂuid of RA patients by anti-human
speciﬁc antibody signiﬁcantly decreased its capability to
induce monocyte migration under diﬀerent chemotactic
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assays. These results clearly showed the relevance of this
chemokine and its receptor in the monocyte migration
through endothelium in the context of RA [54]. However, it
is not yet known whether this pathway could be involved in
the endothelial dysfunction of these patients.
ADAM (a disintegrin and metalloproteases) is a family of
proteases that release a variety of membrane proteins; it has
been reported that ADAM-10 is responsible for releasing dif-
ferent chemokines, like CXCL16 and CX3CL1 [55]. Isozaki
et al. in 2015 reported that the levels of ADAM-10 in serum
from RA patients were signiﬁcantly higher compared to
healthy controls by ELISA; this correlated with the disease
activity measured by DAS28 (disease activity score of 28).
The treatment of the synovial ﬂuid from RA patients with a
speciﬁc antibody against ADAM-10 decreased in vitro
migration of THP-1 cells and monocytes from healthy indi-
viduals. These ﬁndings were corroborated with the
ﬁbroblast-like synoviocytes from patients, which were trans-
fected with speciﬁc siRNA (small interfering RNA) to
ADAM-10 transcription; the silencing of this gene in vitro
inhibited the monocyte and synoviocyte adhesion to the
endothelial cells and decreased growth factor and production
of CX3CL1. These results suggest that ADAM-10 plays an
important role in the monocyte adhesion to inﬂamed tissues
from RA patients and that it could be involved in the endo-
thelial alteration of these patients [55].
In summary, endothelial alterations can occur in RA
patients both in early and chronic states; these can arise in
the microvasculature by IC deposition, causing articular
involvement, deterioration of synovial joints, and in some
cases, a persistent vasculitis (type III hypersensitivity reac-
tions). However, type II mechanisms had also been involved
in the endothelial damage of this disease. Endothelial dys-
function also appears to aﬀect larger vessels of these patients
leading to increased atherosclerosis and the development of
a chronic inﬂammatory process. It is possible that the activa-
tion of patrolling monocytes, for example by IC, participate
in these endothelial abnormalities and increases the vascular
permeability; this could facilitate the articular inﬂammatory
response and the damage of endothelial cells from macro-
vasculature that conduce to plaque formation in RA
(Figure 3). Although it has been described that diﬀerent
molecules can participate in the monocyte-endothelial inter-
action in the context of RA, the exact molecular mechanism
involved and whether this interaction can promote endothe-
lial damage is not yet known. Finally, the apparent inability
of these patients to repair the endothelium could further
perpetuate this tissue damage and increase the risk of suﬀering
vascular complications.
6. Conclusions and Perspectives
RA and SLE are autoimmune diseases that clearly have
micro- and macrovasculature endothelial alterations. Diﬀer-
ent organs and tissues such as kidney, joints, skin, among
others are severely aﬀected by the inﬂammation of the endo-
thelium. The endothelial damage that occurs in these patients
is related to the persistent inﬂammatory response that
characterizes these diseases and is associated with the
presence of autoantibodies, immune complexes, and mono-
cytes activation. It is considered that endothelial compromise
in RA and SLE is due to the direct binding of autoantibodies
to theendothelial cellswhich in turnpromote type IIhypersen-
sitivity reactions, as well as the deposit on the endothelium of
IC ina soluble formoraspartofACandMP(type IIIhypersen-
sitivity reactions). Both mechanisms can increase endothelial
permeability and complement-dependent cytotoxicity and
decrease endothelial junctions, leading to a secondary apopto-
sis of these cells. Finally, these responses induceprothrombotic
activity and leukocyte recruitment to diﬀerent tissues, result-
ing in loss of integrity and function of the endothelium and
underlying tissues (Figure 3). It is considered that some of
these responses could also contribute to the initial endothelial
damage that are required for the accumulation of low density
lipoprotein and formation of atherosclerotic plaques in the
arterial intima of medium and larger vessels, developing a
chronic macrovascular inﬂammatory process.
We proposed that monocytes subpopulations must be
diﬀerentially involved in the initial damage mechanisms of
micro- and macrovasculature. Therefore, depending of the
endothelium, a monocyte subpopulation could diﬀerentially
participate in the inﬂammatory process mediating endothe-
lial damage. Finally, high concentrations of molecules like
PTX3 and CX3CL1 could be used as a biomarker of activa-
tion and endothelial dysfunction in SLE and RA patients.
The mechanisms described here are possibly involved in
endothelial alterations of these diseases; however, further
studies are required in order to better understand the role
of monocytes and their molecules in the endothelial dysfunc-
tion of RA and SLE patients.
Given the role of the endothelium in the pathophysiology
and complications of SLE and RA, as well as other inﬂamma-
tory entities in human, it will be important to get a better
characterization and understanding of the role played by
monocyte subpopulations and IC in the induction of endo-
thelial damage. This could be useful to get new approaches
and therapeutic interventions that can modulate monocyte
responses and interaction with endothelial cells and also to
reduce or prevent endothelial alterations in these diseases
or other chronic inﬂammatory diseases where there is also
a damage of this tissue (Figure 2).
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